Loading organizations...
Loading organizations...
2Flo Ventures: Startup studio and early-stage venture capital firm investing in healthcare innovation, advancing health equity.
Key people at 2Flo Ventures.
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio focused on healthcare innovation and health equity. The firm targets seed through Series B equity investments across the biotechnology, medical device, and digital health sectors to address unmet medical needs in historically underserved communities. Operating with an estimated 11 to 50 employees, the firm is currently raising a targeted $50 million for its inaugural health equity fund. To date, the organization has invested in nine portfolio companies that employ over 100 individuals and have collectively raised more than $85 million in outside capital. The firm's active investment portfolio includes recognizable healthcare startups such as CancerIQ, Partum Health, and Ariel Precision Medicine. 2Flo Ventures was founded in 2021 by Paul Burton and Ibraheem Alinur.
2Flo Ventures is a startup studio and venture capital firm dedicated to accelerating equitable innovation in healthcare. Its mission centers on investing in and building companies that address large unmet medical needs, with a strong emphasis on health equity and inclusion. The firm’s investment philosophy prioritizes diverse healthcare entrepreneurs and startups developing therapeutics, medical devices, diagnostics, and digital health solutions—particularly those focused on closing gaps in health outcomes for underserved communities. 2Flo Ventures typically invests at the pre-seed to Series A stages, supporting early-stage companies that aim to drive meaningful impact in biotechnology and digital health. By combining venture capital with hands-on startup studio support, 2Flo plays a pivotal role in shaping a more inclusive and innovative healthcare ecosystem.
Founded in 2021, 2Flo Ventures emerged from a recognition that systemic disparities in healthcare require targeted investment and operational support. The firm was established by a team of experienced healthcare investors and operators, including Managing Partner Paul Burton, who brings over two decades of experience in corporate finance, strategic advisory, and venture capital. Other key partners include Dr. Charlotte Jones-Burton and Lyle Berkowitz, both of whom have deep backgrounds in healthcare innovation and entrepreneurship. Since its inception, 2Flo has evolved from a traditional VC model into a hybrid startup studio, actively co-founding and scaling companies while also investing in external startups. This dual approach allows 2Flo to not only fund innovation but also directly shape the development of impactful health technologies.
2Flo Ventures is riding the growing trend of mission-driven investing in healthcare, where impact and financial returns are increasingly seen as complementary. The timing is critical, as digital health adoption accelerates and the demand for equitable solutions intensifies in the wake of global health challenges. Market forces—including regulatory shifts, rising healthcare costs, and increased awareness of health disparities—are working in 2Flo’s favor, creating fertile ground for innovative startups that prioritize access and inclusion. By supporting a new generation of health tech entrepreneurs, 2Flo is helping to reshape the healthcare landscape, fostering a more diverse and resilient ecosystem that better serves all communities.
Looking ahead, 2Flo Ventures is poised to expand its influence as it launches new funds and deepens its impact measurement capabilities. The firm’s hybrid model is likely to attract more founders seeking both capital and operational support, while its focus on health equity positions it at the forefront of a broader movement toward inclusive innovation. As healthcare continues to evolve, 2Flo’s ability to identify and nurture breakthrough technologies—especially those addressing systemic gaps—will be increasingly valuable. The firm’s journey reflects a growing recognition that true innovation in health tech must be both impactful and equitable, setting a new standard for what venture capital can achieve in the sector.
Key people at 2Flo Ventures.
